Article

CURE New Issue Alert: Hematology Special Issue

September is Blood Cancer Awareness month and CURE’s latest issue is dedicated to these diseases. And we have a sneak peek at what’s inside:

September is Blood Cancer Awareness month and CURE’s latest issue is dedicated to these diseases. And we have a sneak peek at what’s inside:

Our cover story explores how researchers are Taking a Shot with subcutaneous injections to fight cancers such as multiple myeloma and lymphoma. So far, this method has shown to have fewer side effects and shorter times at the clinic.

Next, A Little of Everything is being used when it comes to treating patients with non-Hodgkin lymphoma. Targeted therapies, immunotherapies and new combinations show promise for the nearly 75,000 adults and children in the United States that are affected by the disease each year.

And, innovative techniques bring new options for people in need of a stem cell transplant. Read the stories of patients who were able to Strike a Match and defy the odds.

Also inside, a team of 16 people walk through “Fire and Ice” for a cause — raising money to help find a cure for multiple myeloma. CURE takes you inside their trek to Iceland.

To read these stories and more, visit https://www.curetoday.com/publications/cure/2018/hematology-2-2018.

Or, ensure you don’t miss a story when you subscribe to new issue alerts. Visit curetoday.com/email-profile for more information.

Related Videos
Image of doctor with grey hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of a woman with a brown hair tied into a bun.
Dr. Mikhael in an interview with CURE